Small Cell Carcinoma clinical trials

Personalized drug test for drug-resistant lung cancer

This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.

Radiation plus anlotinib for lung cancer brain spread

This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.

Testing BEBT-109 for advanced EGFR exon 20 lung cancer

This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.

Targeted therapy plus chemo before surgery for HER2-mutant lung cancer

This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.

Immunotherapy and radiation before surgery for lung cancer

This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.

Testing AWT020 for advanced cancers

This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.

Study of HLX43 for advanced non-small cell lung cancer

This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.

Ivonescimab plus docetaxel for advanced lung cancer

This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.

Metabolic markers predict response to immunotherapy before lung cancer surgery

This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.

Study of a new immune drug for resistant lung cancer

This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.

Megestrol acetate with chemoradiation for stage III lung cancer

This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.

Brain radiation that avoids the memory area in lung cancer

This trial studies a “prophylactic” (preventive) type of brain radiation for people with lung cancer that has spread to nearby lymph nodes but not to the brain. It aims to lower the chance of brain metastases while protecting the hippocampus, an area linked to memory.

Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer

This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.

LM103 after surgery for lung cancer

This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.

Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors

This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.

Tepotinib and Ivonescimab for MET-Driven Lung Cancer

This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.

Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL

This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.

Study on giving immunotherapy less often for advanced cancer

This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.

Testing ZM008 alone and with toripalimab for advanced cancers

This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.

Testing TH9619 for advanced solid tumors

This trial tests a new drug called TH9619 for people with advanced cancers of the colon, head and neck, lung, or stomach. It aims to see if the drug is safe and works against tumors that have already been treated with chemotherapy.

FT836 immune cell therapy for advanced solid tumors

This study tests a new immune cell therapy called FT836, given alone or with chemotherapy or other antibodies, for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if it is safe and helps shrink or control tumors.

Study of a new antibody for advanced tumors with FGFR1 protein

This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer

This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.